Answers are grounded in this paper and cite their sources.
Time-course MBNMA provides a statistically robust framework for synthesising evidence on multiple treatments at multiple time points. The use of placebo-controlled studies in drug-development means there is limited potential for inconsistency. The methods can inform drug-development decisions and provide the rigour needed in the reimbursement decision-making process.
No takes yet. Share an insight, caveat, or question.
Pedder et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: